Pacific Neuropsychiatric Specialists


		a premiere private clinical research company specializing in neuropsychiatric investigations ATP Clinical Research, Inc. 3151 Airway Ave Bldg T, Ste 3 Costa Mesa, CA Tel: 714-277-4472 Fax: 714-545-5748 1) PD-0332334 study with Generalized Anxiety Disorder Age 18-65 Male or Female Diagnosis of Generalized Anxiety Disorder (GAD) Double-Blind study evaluating efficacy, tolerability & safety of PD-00332334 in comparison to Paroxetine (Paxil) & placebo 3/5 chance of receiving PD0332334 Bid, vs. 1/5 chance of Paroxetine (Paxil) vs. 1/5 chance of placebo 12 week study outpatient study 9 scheduled study visits Exclusion criteria-Regular use (5/7 days per week), of benzodiazepines during the 3 months prior to screening Compensation for each completed scheduled study visit Sponsor Pfizer, Inc. 2) Ziprasidone (Geodon)-Efficacy of Switching from Seroquel to Geodon Age 18 & older Male or Female Diagnosis of Schizophrenia or Schizoaffective Disorder Must be on a stable dose of Seroquel only for 3 months Open-label Ziprasidone 40mg Bid vs. 60mg Bid vs. 80mg Bid 32 Week study Outpatient Study 14 scheduled study visits Compensation for each completed scheduled study visit Sponsor Pfizer Inc. 3) Halo Cognition Study Age 18 & older Male or Female Diagnosis of Schizophrenia Only Must be on a stable dose of Geodon, Risperdal or Seroquel for at least 3 months & will continue on their medication 3/4 chance of HALO vs. 1/4 chance of Placebo add on study 12 -Week outpatient study 7 scheduled visits Compensation for completed study visits Sponsor Astra Zeneca 4) Loxapine for Inhalation in Schizophrenic patients with Agitation Age 18 to 65 Male or Female Diagnosis of Schizophrenia Only 1 Scheduled visit 1 day (24-hours) Inpatient, Double-Blind study 2/3 chance of Staccato Loxapine vs. 1/3 chance of Staccato Placebo during the 24 hour hospitalization Compensation for completed study visits Sponsor Alexza Pharmaceuticals, Inc. 5) Asenapine Pharmacokinetics-Elderly Patients w/Psychosis Age 65 & Older Male or Female Must have Psychotic symptoms during time of evaluation Study to evaluate safety & tolerability of Asenapine up 10mg bid in elderly with psychosis No Placebo; Open label study 6-Week study with 8 days Inpatient & if stable then Outpatient Compensation for each completed study visit Sponsor Organon USA, Inc. 6) Dimebon Alzheimer's study Age 50 & Older Male or Female Diagnosis of Probable Alzheimer’s Dementia Study to determine the benefit of Dimebon as compared to Placebo MMSE 10-24 Dimebon 5mg, vs. Dimebon 10mg, vs. Placebo No other Cholinesterase inhibitors or memantine allowed 90 days prior to start of study or during study Must have a caregiver Compensation for completed study visits Sponsor Medivation, Inc. 7) Sanofi Alzheimer's study (Upcoming Study) Male or Female Diagnosis of Probable Alzheimer's Dementia MMSE 12-24 Study to evaluate efficacy & safety of AVE8112 for 24 weeks using donepezil as calibrator in patients with mild-to-moderate Alzheimer's disease 30-Week outpatient Study, 10 scheduled visits, Double-Blind study concomitant treatment of cholinesterase inhibitors and/or memantine not allowed Must have a caregiver Sponsor Sanofi Aventis Group For More Information Contact: Mary Lykke, M.A., LMFT (714) 277-4472 Research Staff Gus Alva, MD, is medical director of ATP Clinical Research. He has served as a principal investigator for the past 10 years conducting investigation in a myriad of neuropsychiatric conditions; Alzheimers and other dementias, depression, anxiety disorders, bipolar disorder and psychotic conditions. As a clinician and investigator, Dr Alva’s focus is on the genetics, neuroimaging, and latest treatments available for each afore mentioned condition, as well as aspects of ethnicity and their correlation within clinical situations. He has published numerous articles, and presents at both national and international meetings and conferences. galva@theatpgroup.net Bobby Shih is a Clinical Research Coordinator at ATP Clinical Research, Inc. Bobby assists in the conducting of the clinical research studies for a myriad of neuropsychiatric aliments, which include Alzheimer’s disease, schizophrenia, and bipolar disorder. While he performs many physical assessments, such as electrocardiograms, vital signs and blood work, Bobby also performs cognitive assessments that assist in gauging the degree of impairment of our patients’ memory and executive functioning. He graduated the University of California , Irvine with a degree in Biological Sciences and Philosophy. bshih@theatpgroup.net

2006 Pacific Neuropsychiatric Specialists, Inc. Copyright Notice \| Disclaimer \| Privacy Statement